Spyre Therapeutics, Inc. (SYRE) research
Spyre Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $87.09
- As of
Spyre Therapeutics, Inc. (SYRE): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.
As of . Source: SEC EDGAR filings for SYRE. Method and limitations.
Share the SYRE intelligence card
See SYRE live in the terminal
Track SYRE's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live SYRE terminal, freeActive signals for SYRE
- highCONSENSUS_BUY
3 tracked funds increased SYRE this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +76% to SYRE (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +314% to SYRE (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 68% of SYRE (2026Q2)
- mediumNEW_POSITION
D. E. Shaw & Co., Inc. new position in SYRE
FREE, NO ACCOUNT
Every signal on SYRE, as it fires
You are seeing 5 of 23 signals recorded on SYRE since 2026-06-05.
The five above landed across 2 days. The other 18 were recorded on 4 other days. 18 of the 23 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SYRE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 00773J202 · 2026Q2 | $17.5M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 00773J202 · 2026Q2 | $9.2M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 00773J202 · 2026Q2 | $2.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 00773J202 · 2026Q2 | $1.1M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SYRE
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SYRE against its peers
SYRE's return on equity of -21.7% ranks in the 52nd percentile of 21 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-03-31.
| Metric | SYRE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 113M USD | 8 | 17 |
| Operating margin | n/a | -101.2% | n/a | 15 |
| Net margin | n/a | -103.6% | n/a | 15 |
| Return on equity | -21.7% | -22.3% | 52 | 21 |
Peers (24): CAI, TGTX, ALKS, IMVT, PRAX, ABVX, IONS, PCVX, IBRX, CRNX, RYTM, BLTE, KYMR, PTGX, CYTK, CGON, NUVL, ARWR, KRYS, SRRK, MIRM, APGE, CNTA, ORKA. Left out: BCHMY (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (SYRE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more SYRE signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to SYREand get the insider, 13F, options, and confluence read in one view.